Jinling Pharmaceutical Co., Ltd. (000919) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jinling Pharmaceutical Co., Ltd.

Why is Jinling Pharmaceutical Co., Ltd. ?

Positive results in Mar 26

OPERATING CASH FLOW(Y) Highest at CNY 264.22 MM
RAW MATERIAL COST(Y) Fallen by -20.65% (YoY)
CASH AND EQV(HY) Highest at CNY 4,336.16 MM

With ROE of 1.44%, it has a very attractive valuation with a 0.81 Price to Book Value

Over the past year, while the stock has generated a return of -9.21%, its profits have risen by 2087.3% ; the PEG ratio of the company is 0
At the current price, the company has a high dividend yield of 1.6

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jinling Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jinling Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Jinling Pharmaceutical Co., Ltd.

-9.09%

-0.14

34.13%

China Shanghai Composite

20.71%

1.56

13.67%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.27%

EBIT Growth (5y)

-34.23%

EBIT to Interest (avg)

72.37

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.35

Sales to Capital Employed (avg)

0.82

Tax Ratio

100.00%

Dividend Payout Ratio

115.34%

Pledged Shares

Institutional Holding

ROCE (avg)

4.77%

ROE (avg)

3.84%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.81

EV to EBIT

87.03

EV to EBITDA

11.85

EV to Capital Employed

0.71

EV to Sales

0.57

PEG Ratio

0.03

Dividend Yield

1.63%

ROCE (Latest)

0.82%

ROE (Latest)

1.44%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 264.22 MM

RAW MATERIAL COST(Y)

Fallen by -20.65% (YoY

CASH AND EQV(HY)

Highest at CNY 4,336.16 MM

PRE-TAX PROFIT(Q)

Highest at CNY 31.4 MM

NET PROFIT(Q)

Highest at CNY 25.65 MM

EPS(Q)

Highest at CNY 0.04

-11What is not working for the Company

INTEREST(9M)

At CNY 3.87 MM has Grown at 13.4%

DEBT-EQUITY RATIO (HY)

Highest at -33.11 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.88 times

NET SALES(Q)

Lowest at CNY 768.67 MM

Here's what is working for Jinling Pharmaceutical Co., Ltd.

Operating Cash Flow

Highest at CNY 264.22 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit

Highest at CNY 31.4 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Pre-Tax Profit

At CNY 31.4 MM has Grown at 108.75%

over average net sales of the previous four periods of CNY 15.04 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 25.65 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Net Profit

At CNY 25.65 MM has Grown at 83.06%

over average net sales of the previous four periods of CNY 14.01 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.04

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Cash and Eqv

Highest at CNY 4,336.16 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -20.65% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Jinling Pharmaceutical Co., Ltd.

Interest

At CNY 3.87 MM has Grown at 13.4%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

Lowest at CNY 768.67 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Debt-Equity Ratio

Highest at -33.11 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 1.88 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio